以前の免疫療法にもかかわらず進行性転移性尿路上皮がん患者の治療のためのペムブロリズマブ プラス CA-4948
転移性尿路上皮がんにおけるPD-1/PD-L1阻害剤に対する耐性を克服するためのCA-4948とペムブロリズマブの併用の第1相試験
This phase I trial tests the safety, side effects, best dose, and effectiveness of emavusertib (CA-4948) in combination with pembrolizumab in treating patients with urothelial cancer that has spread from where it first started to other places in the body (metastatic) and that has a resistance to PD-1/PD-L1 immune checkpoint inhibitors. CA-4948, a kinase inhibitor, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving CA-4948 in combination with pembrolizumab may be safe, tolerable and/or effective in treating patients with metastatic urothelial cancer that is resistant to PD-1/PD-L1 immune checkpoint inhibitors.
調査の概要
状態
詳細な説明
PRIMARY OBJECTIVES:
I. To determine the recommended phase 2 dose of the combination of CA-4948 plus pembrolizumab in patients with immune checkpoint blockade (ICB)-resistant metastatic urothelial cancer (Dose Escalation Cohort).
II. To determine the safety of the combination of CA-4948 plus pembrolizumab in patients with ICB-resistant metastatic urothelial cancer (Dose Escalation Cohort and Dose Expansion Cohort).
SECONDARY OBJECTIVES:
I. To observe and record anti-tumor activity. II. To measure the objective response (complete response [CR] or partial response [PR]) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 at 9 weeks and the best overall response (CR or PR) as defined by RECIST 1.1 at any time while on study.
III. To determine progression-free survival, overall survival, and duration of response.
IV. To assess whether CA-4948 plus pembrolizumab leads to on-treatment increases in 2IR scores (as defined by ribonucleic acid [RNA] sequencing) in paired tumor biopsies.
EXPLORATORY OBJECTIVES:
I. To assess the clinical benefit rate with pembrolizumab plus CA-4948 therapy. II. To assess the "C-reactive protein (CRP) response rate" as defined by the proportion of patients achieving a ≥ 1.5 fold reduction in CRP at 9 weeks.
III. To explore the association between the 2IR score as defined by bulk-ribonucleic acid (RNA) sequencing of pre-treatment tumor tissue and objective response rate, clinical benefit rate, progression-free survival, and/or overall survival.
IV. To explore whether CA-4948 plus pembrolizumab leads to on-treatment changes in the cellular and/or molecular composition of the tumor microenvironment (TME).
V. To explore the association between the quantity and spatial localization of SPP1+ monocytes-macrophages (MoMacs) defined by multiplex immunohistochemistry on pre-treatment tumor tissue and objective response rate, clinical benefit rate, progression-free survival, and/or overall survival.
VI. To explore the association between the cellular and molecular composition of the TME defined by spatial RNA sequencing on pre-treatment tumor tissue and objective response rate, clinical benefit rate, progression-free survival, and/or overall survival.
VII. To explore on-treatment changes in high-sensitivity (hs) CRP and cytokines and chemokines in peripheral blood and their association with objective response rate, clinical benefit rate, progression-free survival, and/or overall survival.
VIII. To explore the association between PD-L1 expression on pre-treatment tumor tissue and objective response rate, clinical benefit rate, progression-free survival, and/or overall survival.
IX. To explore the association between the CXCL9:SPP1 ratio as defined by bulk-RNA sequencing of pre-treatment tumor tissue and objective response rate, clinical benefit rate, progression-free survival, and/or overall survival.
X. To assess whether CA-4948 plus pembrolizumab leads to on-treatment increases in the CXCL9:SPP1 ratio (as defined by RNA sequencing) in paired tumor biopsies.
OUTLINE: This is a dose-escalation study of CA-4948 in combination with pembrolizumab followed by a dose-expansion study.
Patients receive CA-4948 orally (PO) twice daily (BID) on days 1-21 and pembrolizumab intravenously (IV) over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET) throughout the study. Additionally, patients may undergo a tumor biopsy on study.
After completion of study treatment, patients are followed up every 3 months for 2 years.
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
California
-
Duarte、California、アメリカ、91010
- 募集
- City of Hope Comprehensive Cancer Center
-
主任研究者:
- Abhishek Tripathi
-
コンタクト:
- Site Public Contact
- 電話番号:800-826-4673
- メール:becomingapatient@coh.org
-
Irvine、California、アメリカ、92612
- 募集
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
コンタクト:
- Site Public Contact
- 電話番号:877-827-8839
- メール:ucstudy@uci.edu
-
主任研究者:
- Nataliya Mar
-
La Jolla、California、アメリカ、92093
- 募集
- UC San Diego Moores Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:858-822-5354
- メール:cancercto@ucsd.edu
-
主任研究者:
- Tyler Stewart
-
Orange、California、アメリカ、92868
- 募集
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:877-827-8839
- メール:ucstudy@uci.edu
-
主任研究者:
- Nataliya Mar
-
-
Florida
-
Miami、Florida、アメリカ、33136
- 募集
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:305-243-2647
-
主任研究者:
- Jaime R. Merchan
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- 募集
- Emory University Hospital/Winship Cancer Institute
-
コンタクト:
- Site Public Contact
- 電話番号:404-778-1868
-
主任研究者:
- Jacqueline T. Brown
-
Atlanta、Georgia、アメリカ、30308
- 募集
- Emory University Hospital Midtown
-
コンタクト:
- Site Public Contact
- 電話番号:888-946-7447
-
主任研究者:
- Jacqueline T. Brown
-
Atlanta、Georgia、アメリカ、30342
- 募集
- Emory Saint Joseph's Hospital
-
コンタクト:
- Site Public Contact
- 電話番号:404-851-7115
-
主任研究者:
- Jacqueline T. Brown
-
-
New York
-
New York、New York、アメリカ、10029
- 募集
- Mount Sinai Hospital
-
コンタクト:
- Site Public Contact
- 電話番号:212-824-7309
- メール:CCTO@mssm.edu
-
主任研究者:
- Matthew D. Galsky
-
New York、New York、アメリカ、10065
- 募集
- NYP/Weill Cornell Medical Center
-
主任研究者:
- Rohit Jain
-
コンタクト:
- Site Public Contact
- 電話番号:212-746-1848
-
-
Texas
-
Dallas、Texas、アメリカ、75390
- 募集
- UT Southwestern/Simmons Cancer Center-Dallas
-
コンタクト:
- Site Public Contact
- 電話番号:214-648-7097
- メール:canceranswerline@UTSouthwestern.edu
-
主任研究者:
- Waddah Arafat
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Patients must have histologically confirmed urothelial cancer that is metastatic or unresectable and must have had the prior treatments outlined
-
Age ≥ 18 years
- Because no dosing or adverse event data are currently available on the use of CA-4948 in combination with pembrolizumab in patients < 18 years of age, children are excluded from this study, but will be eligible for future pediatric trials
-
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%) within 28 days prior to registration
-
Leukocytes ≥ 3,000/mcL
-
Absolute neutrophil count (ANC) ≥ 1,500/mcL
-
Platelets ≥ 100,000/mcL
-
Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L
- Criteria must be met without packed red blood cell (pRBC) transfusion within the prior 2 weeks. Participants can be on stable dose of erythropoietin (≥ approximately 3 months)
-
Creatine phosphokinase (CPK) < grade (Gr) 2 ( </= 2.5 upper limit of normal [ULN])
-
Creatinine < 1.5 × institutional ULN or creatinine clearance of ≥ 30 mL/min for patient with creatine levels ≥ 1.5 x institutional ULN
- Creatinine clearance (CrCl) should be calculated per institutional standard
-
Total bilirubin ≤ 1.5 x institutional upper limit of normal (IULN)
-
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) ≤ 3 x ULN
-
Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ≤ 3 x ULN
-
International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants
-
Activated partial thromboplastin time (aPTT) ≤1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
-
Ability to provide at least 20 unstained slides or formalin-fixed paraffin-embedded (FFPE) block plus 1 hematoxylin and eosin (H&E) slide from prior archival invasive urothelial cancer specimen (and/or ability to undergo baseline tumor biopsy in patients in the expansion cohort)
-
Measurable metastatic or unresectable disease
-
Must have received prior treatment with a PD-1 or PD-L1 inhibitor
-
Must have received at least one of the following (may have been administered concurrently or sequentially with PD-1/PD-L1 inhibitor):
- Platinum-based chemotherapy
- Enfortumab vedotin
-
Primary resistance to PD-1/PD-L1 blockade as defined by Society for Immunotherapy of Cancer (SITC) consensus definitions:
-
For patients who received single-agent PD-1/PD-L1 blockade in the adjuvant setting:
- Must have received ≥ 6 weeks of treatment with PD-1/PD-L1 blockade
- Recurrence while on treatment or within ≤ 3 months after completion of therapy
-
For patients who received single-agent PD-1/PD-L1 blockade in the metastatic setting:
- Must have received ≥ 6 weeks of treatment with PD-1/PD-L1 blockade
- Progression within ≤ 6 months of initiating treatment with single-agent PD-1/PD-L1 blockade with best response of stable disease
-
For patients who received single-agent PD-1/PD-L1 blockade in the switch-maintenance setting:
- Must have received ≥ 6 weeks of treatment with PD-1/PD-L1 blockade
- Progression within ≤ 6 months of initiating treatment with single-agent PD-1/PD-L1 blockade
-
For patients who received an antibody-drug conjugate or cytotoxic chemotherapy plus PD-1/PD-L1 blockade combination
- Must have received ≥ 6 weeks of treatment with PD-1/PD-L1 blockade
- Progression within ≤ 12 months of initiating treatment
-
An eligibility form will be developed to include documentation of the dates of prior PD-1/PD-L1 blockade and a redacted radiology report confirming best response of stable disease for < 6 months or progressive disease)
-
-
Female patients of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Female patients of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient
-
Male patients of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient
-
HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
Patients who have received messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) and influenza vaccines will be allowed
-
Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging using the identical imaging modality for each assessment, either magnetic resonance imaging [MRI] or computed tomography [CT] scan, for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen
-
Patients should be willing and able to swallow pills
-
Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants
Exclusion Criteria:
- Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) Note: Patients with grade ≤ 2 neuropathy or grade ≤ 2 alopecia are an exception to this criterion and may qualify for the study. Note: If patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
- Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug
- Grade ≥ 3 immune related adverse event with prior PD-1/PD-L1 blockade
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to CA-4948 and/or pembrolizumab
- Patients with uncontrolled intercurrent illness, including but not limited to interstitial lung disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia that would limit compliance with study requirements
- Patients who are receiving any other investigational agents
- Patients with carcinomatous meningitis
- Patients with malabsorption syndrome or other conditions that would interfere with intestinal absorption
- Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
- Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
- Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator
- Has received a live vaccine within 30 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted
- Pregnant women are excluded from this study because pembrolizumab is a monoclonal antibody with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with pembrolizumab, breastfeeding should be discontinued if the mother is treated with pembrolizumab. These potential risks may also apply to other agents used in this study
- Has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] RNA [qualitative] is detected)
- Has a known history of active tuberculosis (TB)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Treatment (CA-4948, pembrolizumab)
Patients receive CA-4948 orally PO BID on days 1-21 and pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection, CT, MRI, or PET throughout the study. Additionally, patients may undergo a tumor biopsy on study. |
Undergo blood sample collection
他の名前:
Undergo CT
他の名前:
Undergo MRI
他の名前:
Undergo PET
他の名前:
Given IV
他の名前:
Undergo tumor biopsy
他の名前:
Given PO
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Dose limiting toxicities (DLTs)
時間枠:Up to completion of cycle 1
|
Adverse events (AEs) will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0. Occurrence of DLTs along with count and percentage of subjects experiencing DLTs will be summarized. Safety of the combination regimen will be summarized by the number of adverse events as well as by the number and percentage of subjects experiencing the adverse events in both dose escalation and expansion cohorts. The safety summary will include count and percentage for overall and by AE type, seriousness, severity, attribution, anticipated or not. Furthermore, toxicity index will be calculated as a summary index for each patient to summarize multiple AEs. |
Up to completion of cycle 1
|
|
Recommended phase 2 dose (RP2D)
時間枠:Up to completion of cycle 1
|
The RP2D may be determined to be the highest dose level, the maximum tolerated dose, or it may be a lower dose based on the consensus of the investigators, Cancer Therapy Evaluation Program and pharmaceutical company collaborators. |
Up to completion of cycle 1
|
|
Incidence of AEs
時間枠:Up to 30 days after last dose of study treatment
|
AEs will be graded using NCI CTCAE v 5.0. Safety will be summarized by the number of AEs as well as by the number and percentage of subjects experiencing the AEs in both the dose escalation and dose expansion phases of the study. The safety summary will include count and percentage for overall and by AE type, seriousness, severity, attribution, anticipated or not. Toxicity will be calculated as a summary index for each patient to summarize multiple AEs. |
Up to 30 days after last dose of study treatment
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective response rate (ORR)
時間枠:At 9 weeks
|
ORR will be defined as the proportion of patients achieving a complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria at 9 weeks. The number of confirmed responses will be reported along with a corresponding two-sided 95% Wilson confidence interval (CI) and p-value will be reported from Binomial exact test. |
At 9 weeks
|
|
Progression-free survival (PFS)
時間枠:At initial treatment to progression or death up to 2 years after last dose of study treatment
|
PFS will be defined as the time from initial treatment to any progression or death from any cause, whichever occurs first. Kaplan-Meier estimates of median PFS time will be presented together with two-sided 95% CIs calculated according to Brookmeyer and Crowley. The frequency (number and percentage) of participants with an event (progression or death) and censoring reasons will be presented (alive, withdrawal of consent, lost to follow-up). |
At initial treatment to progression or death up to 2 years after last dose of study treatment
|
|
Overall survival (OS)
時間枠:At start of study treatment to death up to 2 years after last dose of study treatment
|
OS will be defined as the duration from the first date of study treatment to the date of death. Kaplan-Meyer estimates of median OS will be presented together with two-sided 95% CIs calculated according to Brookmeyer and Crowley. the frequency of participants with an event and censoring reasons will be presented. |
At start of study treatment to death up to 2 years after last dose of study treatment
|
|
Duration of response (DOR)
時間枠:At first response to progression or death up to 2 years after last dose of study treatment
|
DOR will be defined as the time from date of the first documentation of response to the first documentation of progression of disease or death due to any cause in the absence of documented progression of disease. Kaplan-Meier estimates of median DOR time will be presented together with two-sided 95% CIs calculated according to Brookmeyer and Crowley. The frequency of participants with an event and censoring reasons will be presented. |
At first response to progression or death up to 2 years after last dose of study treatment
|
|
2IR scores
時間枠:At baseline and up to 2 years after last dose of study treatment
|
The 2IR score will be calculated using the mean expression levels of the adaptive immune response and pro-tumorigenic inflammation gene signatures from the baseline and on-treatment transcriptome profile derived for each subject. A paired t-test will be used to test whether there is an increase in 2IR score from baseline to on-treatment time points. Univariable logistic regression models will be fitted for response variables with either 2IR score at baseline and change in 2IR score as continuous covariates. Proportional hazard (PH) Cox regression models for PFS and OS will also be fitted with 2IR score either at baseline or as time-dependent continuous covariates. |
At baseline and up to 2 years after last dose of study treatment
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Clinical benefit rate (CBR)
時間枠:At 9 weeks
|
CBR will be defined as the proportion of patients achieving a CR or PR per RECIST 1.1 criteria at 9 weeks or stable disease at 9 weeks accompanied by a 1.5 or greater reduction in hrCRP. CBR will be reported along with a corresponding two-sided 95% Wilson CI and p-value will be reported from Binomial exact test. |
At 9 weeks
|
|
High-sensitivity C-reactive protein (hsCRP)
時間枠:At 9 weeks
|
CRP response rate will be defined as achieving a ≥ 1.5 fold reduction in CRP at 9 weeks. The CRP response rate will be reported along with a corresponding two-sided 95% Wilson CI and p-value will be reported from Binomial exact test. Linear mixed models will also be fitted for comparisons between patients achieving and not achieving an objective response and between patients achieving and not achieving clinical benefit. Random effects with autoregressive model of order 1 will be incorporated to describe the correlation of repeated measures. Univariable PH Cox regression models for PFS and OS will also be fitted with hsCRP levels either at baseline or as a time-dependent continuous covariate. |
At 9 weeks
|
|
Cytokines and chemokines
時間枠:At baseline and up to 2 years after last dose of study treatment
|
Linear mixed models will also be used for comparisons between patients achieving and not achieving an objective response and between patients achieving and not achieving clinical benefit. Random effects with autoregressive model of order 1 will be incorporated to describe the correlation of repeated measures. Residual plots will be used to check model assumptions. Univariable PH Cox regression models for PFS and OS will also be fitted with cytokine and chemokine levels either at baseline or as time-dependent continuous covariates. Schoenfeld residuals will be used to check PH assumption. P-values will be adjusted by false discovery rate of 5%. |
At baseline and up to 2 years after last dose of study treatment
|
|
Multiplex immunohistochemistry markers
時間枠:At baseline and up to 2 years after last dose of study treatment
|
A paired t-test will be used to test whether there are a reduction of SPP1+ MoMacs and an increase in intra-tumoral T cells from baseline to on-treatment time points. Univariable logistic regression models will be fitted for ORR and CBR as response variables with either marker levels at baseline or change in marker levels as continuous covariates. PH Cox regression models for PFS and OS will also be fitted with marker levels either at baseline or as time-dependent continuous covariates. Schoenfeld residuals will be used to check PH assumption. P-values will be adjusted by false discovery rate of 5%. |
At baseline and up to 2 years after last dose of study treatment
|
|
PD-L1 expression
時間枠:Up to 2 years after last dose of study treatment
|
Univariable logistic regression models will be fitted for ORR and CBR as response variables with PD-L1 expression as continuous covariate. Univariable PH Cox regression models for PFS and OS will be fitted with PD-L1 expression as continuous covariate. Schoenfeld residuals will be used to check PH assumption. |
Up to 2 years after last dose of study treatment
|
|
Tumor microenvironment (TME) markers
時間枠:At baseline and up to 2 years after last dose of study treatment
|
A paired t-test will be used to test whether there are a decrease in SPP1+ CD68+ cells and an increase in C1QC+ CD68+ cells from baseline to on-treatment time points. Univariable logistic regression models will be fitted for ORR and CBR as response variables with either TME markers at baseline or change in TME marker levels as continuous covariates. PH Cox regression models for PFS and OS will be fitted with TME markers either at baseline or as time-dependent continuous covariates. Schoenfeld residuals will be used to check PH assumption. P-values will be adjusted by false discovery rate of 5%. |
At baseline and up to 2 years after last dose of study treatment
|
|
Cytometry by time of flight
時間枠:At week 1 of cycles 1-3
|
Will be analyzed using state of the art techniques developed at National Institute of Health and Mount Sinai focused on modeling variance and cellular abundance of these cell populations. The hierarchical nature of the classification and identification of cell types will allow to characterize and identify what populations are affected by treatment and associated with response in the periphery, in contrast with the data obtained at the tumor site (locally), which is identified with spatial assays. |
At week 1 of cycles 1-3
|
|
Extracellular vesicles and particles (EVPs)
時間枠:At week 1 of cycles 1-3
|
Will be analyzed using linear mixed models for longitudinal comparisons, univariable logistic regression for associations with ORR and CBR, and proportional hazards Cox models (including time-dependent covariates) for PFS and OS. Model assumptions will be evaluated using residual diagnostics, including Schoenfeld residuals for PH models. False discovery rate adjustment at 5% will be applied for multiple testing correction. EVP-derived molecular signatures (also known as the secretome) may provide complementary, non-redundant insights beyond those captured by Olink, immunohistochemistry, and spatial transcriptomics, and may identify circulating surrogates of treatment response or resistance. |
At week 1 of cycles 1-3
|
協力者と研究者
捜査官
- 主任研究者:Matthew D Galsky、MOUNT SINAI HOSPITAL
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- NCI-2024-04436
- 10636 (その他の識別子:CTEP)
- NCI-2024-04436 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- 10636 (その他の識別子:NY021 Mount Sinai Hospital)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。